Lunai Bioworks (LNAI) Change in Accured Expenses (2012 - 2026)
Lunai Bioworks (LNAI) posted quarterly Change in Accured Expenses of -$30857.0 for Q1 2026, down 3085800.0% year-over-year from N/an in Q1 2025, and down 110.49% quarter-over-quarter from $294279.0 in Q4 2025.
Lunai Bioworks (LNAI) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Lunai Bioworks' Change in Accured Expenses history runs 15 years deep, the most recent figure standing at -$30857.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 3085800.0% year-over-year to -$30857.0; the TTM figure through Mar 2026 stood at $305382.0 (up 113.5% YoY), while the FY2025 annual figure was -$26477.0, changed N/A from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$30857.0, down from $294279.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $2.2 million in Q1 2024, with the low at -$2.2 million in Q2 2024.
- The 5-year median for Change in Accured Expenses is -$9259.5 (2022), against an average of $52956.8.
- The sharpest annual moves came in 2024 and 2026: Change in Accured Expenses soared 756.24% in 2024, then slumped 3085800.0% in 2026.
- Lunai Bioworks' Change in Accured Expenses stood at -$50034.0 in 2022, then slumped by 113.11% to -$106626.0 in 2023, then rose by 6.44% to -$99763.0 in 2024, then soared by 394.98% to $294279.0 in 2025, then sank by 110.49% to -$30857.0 in 2026.
- Business Quant data shows LNAI's Change in Accured Expenses at -$30857.0 in Q1 2026, $294279.0 in Q4 2025, and $41960.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | 11,049.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30,857.00 |
| Mar 31, 2026 | -30,857.00 |
| Dec 31, 2025 | 294,279.00 |
| Dec 31, 2025 | 294,279.00 |
| Jun 30, 2025 | 41,960.00 |
| Jun 30, 2025 | 41,960.00 |
| Mar 31, 2025 | 1.00 |
| Mar 31, 2025 | 1.00 |
| Dec 31, 2024 | -99,763.00 |
| Dec 31, 2024 | -99,763.00 |
| Sep 30, 2024 | 31,325.00 |
| Sep 30, 2024 | 31,325.00 |
| Jun 30, 2024 | -2.19 Mn |
| Jun 30, 2024 | -2.19 Mn |
| Mar 31, 2024 | 2.22 Mn |
| Mar 31, 2024 | 2.22 Mn |
| Dec 31, 2023 | -106,626.00 |
| Dec 31, 2023 | -106,626.00 |
| Sep 30, 2023 | 77,055.00 |
| Sep 30, 2023 | 77,055.00 |